Scholar Rock Holding Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 19, 2024. Scholar Rock is a clinical-stage biopharmaceutical company; it has no approved products and has generated no commercial product revenue.
Business context and pipeline
- Apitegromab: Investigational myostatin inhibitor being tested as an add-on muscle-targeted therapy for nonambulatory Type 2 and Type 3 spinal muscular atrophy (SMA). The Phase 3 SAPPHIRE trial completed enrollment in 2023; top-line results were expected in Q4 2024.
- SRK-181: Latent TGFβ1 inhibitor being studied with checkpoint inhibitor therapy in resistant solid tumors. The Phase 1 DRAGON trial completed enrollment in December 2023. Management cited preliminary proof-of-concept activity in clear cell renal cell carcinoma (ccRCC).
- SRK-439: Preclinical myostatin inhibitor for cardiometabolic conditions, including obesity. The company planned a potential IND submission in 2025 and a 2024 Phase 2 apitegromab study with a GLP-1 receptor agonist to inform the program.
- Additional discovery and preclinical programs target fibrosis and iron-restricted anemia, among other areas.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0 | $33.2 million |
| Research and development expense | $121.9 million | $124.4 million |
| General and administrative expense | $49.4 million | $43.1 million |
| Total operating expenses | $171.3 million | $167.6 million |
| Loss from operations | $171.3 million | $134.4 million |
| Other income (expense), net | $5.5 million | $(0.1) million |
| Net loss | $165.8 million | $134.5 million |
| Net loss per share, basic and diluted | $(1.99) | $(2.26) |
| Net cash used in operating activities | $145.2 million | $132.7 million |
- The FY2022 revenue was a one-time $33.2 million recognition of deferred Gilead collaboration option consideration after Gilead terminated its option period; it was not recurring product revenue. The filing reports no gross margin or product margin, as there were no product sales.
- R&D expense declined 2.0%, mainly on lower apitegromab clinical-supply costs, partly offset by higher SRK-181 trial costs and internal personnel expenses. G&A expense rose 14.6%, including higher compensation and professional-services costs.
- Cash, cash equivalents and marketable securities totaled $279.9 million at year-end, down from $315.4 million. Management estimated these resources would fund operating expenses and capital requirements into the second half of 2025, based on its then-current plan; it also stated additional capital would be needed to complete clinical development and commercialization.
- Operating cash use increased year over year. Financing provided $102.6 million, primarily from the October 2023 equity offering; investing activities provided $41.1 million, mainly reflecting marketable-security maturities and purchases.
- Debt carrying value was approximately $50.0 million ($1.3 million current and $48.7 million long-term). The loan’s stated maturity was November 2027, with interest-only payments through November 2024, or potentially November 2025 subject to milestones; principal payments were scheduled to begin thereafter. The rate is the greater of prime plus 4.60% or 9.35%.
- Year-end current assets were $288.2 million and current liabilities were $32.7 million. The filing does not provide a company-defined liquidity ratio or quarterly Q4 financial results in the supplied text.
Material changes and notable items
- Net loss widened by $31.3 million, or 23.3%, despite higher interest income and modestly lower R&D expense; the prior-year one-time collaboration revenue did not recur.
- The company raised approximately $92.4 million net in an October 2023 public offering. Shares issued and outstanding increased to 76.0 million at year-end from 51.7 million a year earlier. Additional potential dilution includes 19.5 million outstanding pre-funded warrants and 10.0 million common warrants.
- In October 2023, Scholar Rock expanded its focus to cardiometabolic disease, including obesity. Management expected G&A spending to rise with commercial-readiness investment and expected SRK-181 costs to decrease after DRAGON enrollment completion.
- The 2022 workforce reduction affected 39 positions; related severance and modification costs were recorded in 2022, and the filing says those amounts were paid by year-end 2022.
Outlook, risks and contingencies
- Management’s key near-term catalyst was SAPPHIRE top-line data expected in Q4 2024. A commercial launch in 2025 was conditional on successful results and regulatory approval; neither approval nor launch is assured.
- Management reported that 6 of 28 evaluable ccRCC patients in the DRAGON cohort had confirmed partial responses (21.4% objective response rate) in data through August 29, 2023. These were early clinical results, and the filing cautions that preliminary data may change; the study was not described as a definitive efficacy demonstration.
- TOPAZ 36-month extension results were reported as observed-case analyses: mean HFMSE change of +4.0 and RULM change of +2.4 among nonambulatory patients. These Phase 2 extension findings do not establish Phase 3 success.
- Principal risks include clinical-trial failure or delay, regulatory uncertainty, the need for additional financing, potential dilution, limited manufacturing capacity and reliance on third parties. The company relies on a single-source manufacturer for apitegromab and SRK-181 and has no long-term supply agreements.
- Two European patents, EP2981822 and EP3368069, were subject to opposition proceedings as of year-end. The company reported no material legal proceedings and no cybersecurity incident that had materially affected it or was reasonably likely to materially affect it.
- The auditor issued an unqualified opinion on the financial statements. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not attest to internal-control effectiveness because the company qualified as a smaller reporting company.
Important facts for investors to verify
- Whether SAPPHIRE met its primary endpoint and safety objectives, and whether subsequent regulatory filings and review support the proposed timeline.
- Cash burn, financing needs and actual cash runway as clinical and potential launch spending evolve; the runway estimate is based on management assumptions.
- Final and centrally reviewed DRAGON data, including durability, safety, biomarker findings and results across all tumor cohorts.
- Whether the planned obesity study starts on schedule, access to GLP-1 therapy, and progress toward SRK-439 IND-enabling studies.
- Debt terms and repayment schedule, remaining ATM capacity, warrant exercises and other potential share dilution.
- Manufacturing readiness and supply continuity, as well as outcomes of the European patent opposition proceedings.